Coronary Angiography in Post-CABG PatientsCoronary Angiography in Post-CABG Patients
Can transradial angiography be safely performed in patients with coronary grafts, without significant increase in procedural time or radiation exposure? The Journal of Invasive Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 14, 2016 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
PCI Post CABG: Native Arteries Fare Better Than Vein Grafts
(MedPage Today) -- Study found more adverse outcomes when intervening in a bypass graft (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 13, 2016 Category: Cardiology Source Type: news
Selective Valve Repair at CABG in Moderate Ischemic MRSelective Valve Repair at CABG in Moderate Ischemic MR
Despite no net clinical gain from adding valve repair to CABG for moderate ischemic mitral regurgitation overall, the combined surgery may be appropriate in some cases, researchers say. Heartwire from Medscape (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 8, 2016 Category: Surgery Tags: Cardiology News Source Type: news
ACC: Prophylactic Magnesium Shows Hints of Preventing Post-CABG Afib (CME/CE)
(MedPage Today) -- But clear benefit seen only in one subgroup (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 6, 2016 Category: Cardiology Source Type: news
No improvements with losmapimod after heart attack
Patients taking losmapimod, an anti-inflammatory drug currently being developed, for 12 weeks following a heart attack did not show improvements in the trial's primary endpoint, the rate of cardiovascular death, subsequent heart attack or urgent coronary revascularization, which includes placement of a stent or coronary artery bypass surgery, according to new research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 4, 2016 Category: Science Source Type: news
STICHES: CABG Boosts 10-Year Survival in Severe LV DysfunctionSTICHES: CABG Boosts 10-Year Survival in Severe LV Dysfunction
"It's a very clear indication that if you have low ejection fraction that you should seriously consider whether revascularization is feasible," says an expert observer. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 4, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news
ACC: After a Decade, CABG Pulls Ahead of Meds for HF
(MedPage Today) -- Life-saving benefit of CABG now clear in long-term trial follow-up (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 4, 2016 Category: Cardiology Source Type: news
ACC: Still No Benefit to CABG, Mitral Valve Fix Combo
(MedPage Today) -- Endpoints at 2 years no better for combination procedure than at 1 year (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 4, 2016 Category: Cardiology Source Type: news
No improvements with losmapimod after heart attack
(American College of Cardiology) Patients taking losmapimod, an anti-inflammatory drug currently being developed, for 12 weeks following a heart attack did not show improvements in the trial's primary endpoint, the rate of cardiovascular death, subsequent heart attack or urgent coronary revascularization, which includes placement of a stent or coronary artery bypass surgery, according to research presented at the American College of Cardiology's 65th Annual Scientific Session. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 4, 2016 Category: Global & Universal Source Type: news
Bypass Surgery Is Shown to Extend Survival in Heart Failure
In this study, 20 percent of patients assigned to drug therapy alone had undergone bypass surgery by the end of the study.
Study co-author George Sopko, M.D., a program director within the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute (NHLBI), said the long-term analysis of CABG among patients with severe heart disease is important for clinical practice.
“There are risks associated with all surgical procedures, so the benefits need to be followed for a long time,” Sopko said. “If surgery can be done with reasonable risk and extends life, it becomes the recommended approach.”
T...
Source: DukeHealth.org: Duke Health Features - April 3, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news
Pavmed extends $6m IPO
Pavmed said earlier this week it will extend its heavily reduced $6 million IPO an additional 45 days.
The IPO was dramatically reduced in January, with the company announcing that it planned to float a reduced 1.2 million shares at $5 a piece. Pavmed expects the IPO to bring in $5.4 million after sales commissions but before expenses. The offering includes an 800,000-share over-allotment option, the company said.
That’s a far cry from the $23 million top end Pavmed listed when it registered the IPO last May. Pavmed is developing devices in 5 areas, according to its IPO registration: The PortIO long-term implantable...
Source: Mass Device - March 18, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Pavmed Source Type: news
Aspirin Before CABG Does Not Increase Bleeding Risk, Says StudyAspirin Before CABG Does Not Increase Bleeding Risk, Says Study
"It's almost embarrassing" that this type of study hasn't been done before, said an expert about the randomized aspirin-vs-placebo trial of 2100 patients. "This is good evidence that it's safe." Heartwire from Medscape (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 25, 2016 Category: Surgery Tags: Cardiology News Source Type: news
Studying for USMLE Step 2? Master this most missed question
Studying for the United States Medical Licensing Examination® (USMLE®) Step 2 may seem daunting, but not to fear. Starting this month, we’re giving you an exclusive scoop on the most missed USMLE Step 2 test prep questions and expert strategies to help you beat them. Check out this month’s most challenging question, and view an expert video explanation of the answer from Kaplan Medical.
Welcome to the first Step 2 post in AMA Wire’s® series, “Tutor talk: Tips from Kaplan Medical on the most missed USMLE test prep questions from Kaplan’s Qbank.” Each month, we’re revealing the top questions students miss...
Source: AMA Wire - February 24, 2016 Category: Journals (General) Authors: Amy Farouk Source Type: news
Pavmed scales back IPO to $6m
Pavmed last week dramatically trimmed its pending initial public offering, saying it plans to float 1.2 million shares at $5 apiece for gross proceeds of $6 million.
That’s a far cry from the $23 million top end Pavmed listed when it registered the IPO last May. Pavmed is developing devices in 5 areas, according to its IPO registration: The PortIO long-term implantable vascular access device; the Caldus line disposable tissue ablation devices, including renal denervation for hypertension; the CarpX percutaneous device to treat carpal tunnel syndrome; the NextCath self-anchoring short-term catheter; and the NextFlo d...
Source: Mass Device - January 25, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Initial Public Offering (IPO) Wall Street Beat Cruzar Medsystems Kaleidoscope Medical Pavilion Medical Innovations Pavmed Saphena Medical Vortex Medical Source Type: news
PCI vs CABG: A Surgeon and Interventionalist DiscussionPCI vs CABG: A Surgeon and Interventionalist Discussion
Surgeon Dr Kappetein and interventional cardiologist Dr Pyo discuss the various indications for PCI vs CABG, and their preferred revascularization strategy for different types of patients. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 23, 2016 Category: Cardiology Tags: Cardiology Expert Interview Source Type: news
